Clinical Trials Logo

Pancreatitis clinical trials

View clinical trials related to Pancreatitis.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 7

NCT ID: NCT03215862 Not yet recruiting - Clinical trials for Post-ERCP Acute Pancreatitis

Lactated Ringer's Solution to Prevent Post-ERCP Pancreatitis

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

This is a randomized, double-blinded, controlled trial. This study is a head to head comparison of normal saline (NS) infusion versus Lactated Ringer's (LR) infusion in patients, with the primary outcome of post-ERCP pancreatitis occurrence. Patients will be randomized to either the NS infusion group or the LR infusion group. IVF will be started pre-procedurally and will be continued throughout the procedure. A IVF bolus will be given at the end of the procedure and then continued as a continuous infusion. Our null hypothesis is that there will be no significant difference in the rate of occurrence of post-ERCP pancreatitis between the infusion of LR and NS solutions. Our alternative hypothesis is that patients receiving LR solution infusion will experience a decreased rate of post-ERCP pancreatitis compared to patients receiving NS solution infusion.

NCT ID: NCT03082469 Not yet recruiting - SIRS Clinical Trials

Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal

PACIFIC
Start date: March 15, 2017
Phase: Phase 4
Study type: Interventional

Severe acute pancreatitis (SAP) has a mortality of up to 42%. The outcome of SAP is related to the development of SIRS and consecutive organ failures. Due to the lack of a causative therapy except the removal of bile duct stones, therapy is predominantly symptomatic. With regard to a marked inflammatory response ("cytokine storm") during the early phase of SAP extracorporeal cytokine removal is a promising therapeutic approach. This prospective case control study investigates the impact of early extracorporeal cytokine adsorption with the CytoSorb®-device on haemodynamics (primary endpoint) and several secondary outcomes.

NCT ID: NCT02964403 Not yet recruiting - Pancreatitis, Acute Clinical Trials

COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis

Start date: December 2016
Phase: Phase 4
Study type: Interventional

Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a "standard" method to prevent PEP. The mechanism of indomethacin is dependent on COX-2 inhibitor. According to data, we design the project. The purpose of this study is to determine whether COX-2 inhibitor is effective on control of Post-ERCP pancreatitis.

NCT ID: NCT02947932 Not yet recruiting - Clinical trials for Gastrointestinal Disease

Oral Resveratrol to Prevent Post-ERCP Pancreatitis

Start date: December 2016
Phase: Phase 4
Study type: Interventional

Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a "standard" method to prevent PEP. However, the risk factors of PEP is not fully clear. Additionally, the complication of NSAID use lead to some serious physical problem bleeding. Therefore, the exclusive criteria for limiting the NSAID use is including allergy, gastrointestinal haemorrhage ,presence of coagulopathy or received anticoagulation therapy. Previous study showed that another natural compound, resveratrol, owns similar biological effect with NSAID. Firstly, it could inhibit the inflammatory response on in vivo model through inhibition of COX and IL-6 etc. Secondly, it could not influence the level of platelet and coagulation, which means safer than NSAID. Thirdly, numerous studies showed that resveratrol could effectively the progression of severe acute pancreatitis. According to data, we design the project. The purpose of this study is to determine whether oral resveratrol pre-ERCP is effective on control of Post-ERCP pancreatitis.

NCT ID: NCT02691598 Not yet recruiting - Clinical trials for Pancreatitis, Acute Necrotizing

Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following Severe Acute Pancreatitis

DHPOFFSAP
Start date: February 2016
Phase: Phase 4
Study type: Interventional

Cytokines such as such as TNF-a, IL-1, IL-6 correlate with the severity of pancreatitis.Neuroendocrine pathways, such as the sympathetic nervous system or parasympathetic nervous system, in turn, have some impact on the immune systems, through a-2 adrenoreceptor stimulation or the cholinergic anti-inflammatory pathway. The investigators aim to use Dexmedetomidine Hydrochloride to decrease the activity of sympathetic nervous system, thus relieve inflammation response.

NCT ID: NCT02433444 Not yet recruiting - Pancreatitis Clinical Trials

Computer Aided, Non-invasive, Acoustic Gastrointestinal Surveillance in Post-ERCP Pancreatitis

Start date: May 2015
Phase: N/A
Study type: Observational

In this study, the investigators aim to distinguish patients with Post-Endoscopic retrograde cholangiopancreatography (ERCP) Pancreatitis (PEP) vs. those without PEP based on difference in pre- vs. post-ERCP measurements of AGIS-derived intestinal rates (IR). Based on the clinical observation that many patients with PEP develop ileus following ERCP, the investigators hypothesize that patients who develop PEP will exhibit lower IR following ERCP, and therefore a larger difference in pre- vs. post-ERCP IR.

NCT ID: NCT00508729 Not yet recruiting - Clinical trials for Pancreatitis, Acute Necrotizing

Effect of Traditional Chinese Medicine on GI Function Recovery and Nutrition Support in SAP

Start date: October 2007
Phase: Phase 2/Phase 3
Study type: Interventional

With multicenter randomized control clinical evaluation investigations, the effect of traditional Chinese medicine on gastrointestinal function recovery and nutrition support in early stage of severe acute pancreatitis (SAP) was evaluated, and the therapeutic effects, safety and indications assured. Drawing in latest research fruits at home and abroad, a clinical practical guideline would be formed, to be popularized all over China.